At a glance
| Common trade context | Argireline |
|---|---|
| Older ingredient name | Acetyl hexapeptide-3 |
| Molecular size | Six amino acids |
| Studied use | Topical periocular wrinkle appearance |
| Different ingredient | Acetyl octapeptide-3 / SNAP-8 |
Overview
This six-amino-acid ingredient was previously described as acetyl hexapeptide-3; the older name appears in research and should be searchable as an alias. It is chemically different from acetyl octapeptide-3, despite the easily confused numbers. The cosmetic rationale concerns expression-related lines, but evaluating that claim requires more than a laboratory mechanism. A topical product must preserve the peptide and deliver it to a relevant site, while its moisturizer base can independently change the appearance of fine lines. Human evidence is therefore best interpreted at the level of the tested formulation, duration, and measurement method.
How it works
The peptide was designed from a region of SNAP-25, a protein involved in the SNARE machinery used for vesicle release. Experimental work proposes interference with transmitter-release processes. That is a different molecule and mode of delivery from botulinum toxin. Demonstrating a proposed interaction in a laboratory does not show that a cosmetic cream reaches human neuromuscular targets with an equivalent magnitude or duration of effect.
The randomized human study
A four-week trial randomized sixty Chinese participants to an Argireline formulation or placebo in a three-to-one ratio. Subjective grading and silicone-replica analysis favored the active preparation. The small sample and short follow-up limit conclusions about persistence, uncommon adverse effects, and performance of other products containing the same ingredient.
Supporting sources [1]
Why the older name matters
A separate small study used the name acetyl hexapeptide-3 and examined it alone or with tripeptide-10 citrulline. That is evidence concerning acetyl hexapeptide-8’s historical naming, not evidence for acetyl octapeptide-3. Confusing the names would assign a clinical study to the wrong molecule.
Cosmetic evidence has a defined scope
The CIR document reviews this ingredient in cosmetic use and clarifies its naming; its conclusions cannot be extended to injection or arbitrary formulations. Cosmetic status is not FDA drug approval. The finished product’s tolerability, vehicle, and stability remain relevant to interpreting any reported benefit.
Frequently asked questions
Is acetyl hexapeptide-3 the same as acetyl hexapeptide-8?
It is an older name for the ingredient described here. Acetyl octapeptide-3 is a different molecule.
Is Argireline proven equivalent to Botox?
No. Small topical cosmetic studies measured wrinkle appearance, not clinical equivalence to injected botulinum toxin. Molecule, delivery, exposure, magnitude of effect, and duration all differ.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Acetylated and amidated synthetic hexapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Argireline in Chinese subjects: randomized placebo-controlled wrinkle study ↗Clinical trial source · Checked 2026-10-27
- Acetyl hexapeptide-3 and tripeptide-10 citrulline: randomized formulation study ↗Clinical trial source · Checked 2026-10-27
- CIR revised tentative assessment of acetyl hexapeptide-8 amide: identity and cosmetic-use data ↗Ingredient assessment · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27